<?xml version="1.0" encoding="utf-8" ?>
<feed xmlns="http://www.w3.org/2005/Atom">
<title>Abbomax - Latest News</title>
<link href="https://news.prfree.org/rss/abbomax/latest.xml"></link>
<updated>2026-07-21T19:21:12+00:00</updated>
<id>urn:uuid:15682498-63bf-4469-0555-a6f70763d4db</id>
<entry>
<title>Scientists at AbboMax developed antibodies against PINK1 and Parkin to study Parkinson’s disease</title>
<link href="https://news.prfree.org/@abbomax/scientists-at-abbomax-developed-antibodies-against-pink1-and-parkin-to-study-parkinson-s-disease-ypm436j6wk85"></link>
<id>urn:uuid:6e504dea-2e00-b062-42aa-f68f84892e7f</id>
<summary type="html"><![CDATA[A panel of PINK1 and Parkin antibodies was developed at Abbomax to investigate Parkinson’s disease (PD). These phosphospecific and paired antibodies would be the useful tools for studies of PINK/Parkin pathways and signaling in PD.]]></summary>
<updated>2019-05-07T19:53:18+00:00</updated>
</entry>
</feed>